Thursday 16 October, 2025
Context: The high rate of failure observed in clinical trials evaluating antidepressant agents is mainly explained by a marked placebo…
Read morePoster: Other Drug/Disease Modelling
Development of a mechanistic based model for neonatal Fc receptor recycling to design human serum albumin mutants with extended half-lives
Thursday 16 October, 2025
Objectives: Similar to immunoglobulins, increasing the pH dependent affinity of binding to neonatal Fc receptor (FcRn) is a possible strategy…
Read moreSemi-mechanistic Multiple-analyte Population Model of Antibody-drug-conjugate Pharmacokinetics
Thursday 16 October, 2025
Objectives: Monomethyl auristatin E (MMAE) containing antibody-drug-conjugates (ADCs) are complex mixtures, therefore their pharmacokinetics are assessed by evaluating multiple analytes…
Read moreA semi-physiological model for rifampicin and rifapentine CYP3A induction on midazolam pharmacokinetics.
Thursday 16 October, 2025
Objectives: Rifamycins are antibiotics largely used in the treatment of tuberculosis and are potent inducers of a wide range of…
Read moreModelling of disease progression and drug effects in preclinical models of neuropathic pain
Thursday 16 October, 2025
Background: Neuropathic pain arises as direct consequence of a lesion or disease affecting the somatosensory system. Despite the wide range…
Read moreMechanism-based assessment on the pharmacodynamics of neuromuscular relaxants and general consideration for receptor blockers
Thursday 16 October, 2025
Objectives: Neuromuscular relaxants exert the pharmacological effect blocking nicotinic receptors at neuromuscular junction. For the pharmacodynamics, 1) in vitro affinity…
Read moreA Novel Pharmacodynamic Modeling Approach to Determine Long Term Disease Progression Rates in Japanese Type 2 Diabetes Patients: Pioglitazone vs. Conventional Therapy
Thursday 16 October, 2025
Objectives: Type 2 diabetes mellitus (T2DM) is a slowly progressing disease, making changes in disease trajectory difficult to assess in…
Read moreMixed Effects Modeling to Quantify the Effect of Empagliflozin Exposure on the Renal Glucose Threshold in Patients with Type 2 Diabetes Mellitus
Thursday 16 October, 2025
Objectives: Empagliflozin, a selective and potent SGLT2 inhibitor, reduces renal glucose reabsorption by lowering the renal threshold for glucose (RTG) leading…
Read morePopulation Analysis of wet-AMD Disease Progression and The Therapeutic Effect of Ranibizumab
Thursday 16 October, 2025
Objectives: The aim of this study was to develop a population based model to describe the disease progression of the…
Read morePopulation pharmacokinetic analysis in healthy volunteers treated with different oral formulations of riluzole.
Thursday 16 October, 2025
Objectives: The aim of the current study was to develop a population model to assess the PKs of riluzole administered…
Read more